Is increased activator protein 1 in cerebrospinal fluid as a potential biomarker that distinguishes idiopathic intracranial from sclerosis?

Basit Öğe Kaydı
dc.authoridAydin Turkoglu, Sule/0000-0001-8616-832X
dc.authoridAnkarali, Handan/0000-0002-3613-0523
dc.authoridDURSUN, ALI DOGAN/0000-0001-9056-0025
dc.contributor.authorKarabork, Seyda
dc.contributor.authorCelik, Humeyra
dc.contributor.authorDursun, Ali Dogan
dc.contributor.authorAnkarali, Handan
dc.contributor.authorTurkoglu, Sule Aydin
dc.date.accessioned2024-09-25T19:58:58Z
dc.date.available2024-09-25T19:58:58Z
dc.date.issued2024
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractOBJECTIVES: To distinguish whether idiopathic intracranial hypertension (IIH) is a condition predisposing to multiple sclerosis (MS) or an isolated disease, the current gene transcription factor Activator Protein -1 (AP -1) was evaluated with its potential to differentiate both diseases. BACKGROUND: The aim of this study was to investigate the use of AP -1 as biomarkers for the discrimination of IIH and MS. METHODS: AP -1, TNF-alpha, and IL -6 protein values in the CSF of the cases were evaluated by the ELISA method. The numerical measures of the groups and the ability of AP -1 to distinguish the groups were analyzed with the ROC curve. RESULTS: There was no difference between the groups in CSF TNF-alpha, IL -6, CSF, and serum biochemistry analyses. However, it was determined that the AP -1 concentration (pg/ml) was significantly higher in the IIH group, the sensitivity of AP -1 in separating those with IIH was 75%, and the specificity in separating those with MS was 60% in those with an AP -1 concentration of 606.5 and above. CONCLUSION: According to our results, the fact that CSF TNF-alpha and IL -6 values did not differ in IIH compared to MS revealed that IIH could not methodologically control MS, and AP -1 was a supportive parameter in differentiating both diseases (Tab. 2, Fig. 1, Ref. 31) . Text in PDF www.elis.sken_US
dc.identifier.doi10.4149/BLL_2024_58
dc.identifier.endpage386en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue6en_US
dc.identifier.pmid38757596en_US
dc.identifier.scopus2-s2.0-85193478014en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage382en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2024_58
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13833
dc.identifier.volume125en_US
dc.identifier.wosWOS:001235481100004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAepress Sroen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectmultiple sclerosisen_US
dc.subjectidiopatic intracranial hypertensionen_US
dc.subjectactivator protein-1en_US
dc.subjectcerebrospinal fluiden_US
dc.subjectinflammationen_US
dc.titleIs increased activator protein 1 in cerebrospinal fluid as a potential biomarker that distinguishes idiopathic intracranial from sclerosis?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu